-
$GNPX Be on the lookout for the compliance PR. The co. Obviously didn’t want to use all their PRs in one day. -
$VERB DISRUPTIVE TECHNOLOGY FLYING UNDER MOST RADARS
STILL BARELY OFF 5 YEAR LOWS #OPPORTUNITY
NOW OVER 937,000 MEMBERS AND BOOMING
VERB HAS RUN +1000% FROM THIS LEVEL (TWICE)
BIG TECH INTEGRATIONS
$ALT$NNVC$NVAX$MRNA$INPX$GNPX$TTPH$BLRX$EXPR$IBIO$CYCN$NIOpic.twitter.com/T0IIIgrriCVERB THE ULTIMATE BOTTOM PLAY--SEVERELY UNDERVALUED♥ Patent pending Zoom killer platform ♥Big Tech Partners & a Backlog of Clients To On-board ♥Analyst Reports 100's of % Above Current Market ♥Ran over 1000% TWICE From This Level Before -
$GNPX to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC) -
$GNPX Has a massive upside potential for a very BIG move up next week... i do t usually mess around with anything over 1$ range but that massive flag caught my eye
. I’m adding here first thing 4 a.m Monday morning. That being said GL take your profits rinse and repeat. 
-
-
$GNPX breast cancer too. https://www.genprex.com/news/independent-researchers-find-genprexs-tusc2-prevents-tumor-growth-in-triple-negative-breast-cancer/ … Photo and data from company presentation available on their websitepic.twitter.com/ba777KkVQe
-
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

Biggest Market Losers


THIS IS A INDUSTRY DISRUPTOR WORTH LOOKING INTO AND AT 5 YEAR LOWS